ImmunoGenesis Showcases Breakthrough Therapy for Glioblastoma at AACR 2026
ImmunoGenesis Exhibits Cutting-Edge Therapy for Glioblastoma at AACR 2026
ImmunoGenesis, a pioneering biotech firm dedicated to developing advanced immunotherapies, is poised to unveil new findings regarding its promising treatment for glioblastoma multiforme (GBM) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. This event is scheduled to take place from April 17 to April 22 in sunny San Diego, California.
At this conference, ImmunoGenesis will present a poster that delves into its investigational new drug (IND) enabling work for IMGS-203, a groundbreaking stimulator of interferon genes (STING) agonist. This innovative approach is particularly designed for the treatment of GBM, a notoriously aggressive brain cancer that is often characterized by a highly immunosuppressive tumor microenvironment.
Overview of IMGS-203
In clinical models for GBM, IMGS-203 has demonstrated remarkable anti-tumor activity, facilitating significant survival benefits. The therapy is ingeniously designed for intratumoral delivery, ensuring localized immune activation while minimizing systemic exposure. During the poster presentation, detailed results will be shared from pharmacologic activity assessments across multiple species, coupled with pilot toxicology studies that lay the groundwork for translation into clinical research.
Dr. Federica Pericle, the Chief Scientific Officer at ImmunoGenesis, emphasized the importance of this development: "IMGS-203 combines strong STING activation with a targeted delivery strategy, crafted to counteract the immunosuppressive nature of the GBM microenvironment. These findings clearly set the path for the advancement of IMGS-203 into clinical development."
Clinical Context
GBM remains one of the most lethal malignancies due to its complex interactions with the immune system, characterized by a tumor microenvironment rife with myeloid-derived suppressor cells, and tumor-associated macrophages and neutrophils. The delivery method of IMGS-203 positions it favorably for treating this type of cancer, as GBM typically doesn't metastasize outside the brain and easily allows for local administration during routine biopsy processes.
In vitro and preclinical murine studies have illuminated the antitumor efficacy of IMGS-203, revealing not just its specific mechanisms of action, but also providing critical pharmacokinetic data that reinforce its translational potential for localized treatment.
Presentation Details
- - Title: IND-enabling development of a novel STING agonist, IMGS-203, for the treatment of glioblastoma
- - Abstract Number: 4300
- - Date and Time: Tuesday, April 21, 2026, from 9:00 AM to 12:00 PM PT
- - Session: Immunomodulatory Agents
- - Location: Poster Section 8, Poster Board Number 4
For those attending the AACR Annual Meeting, further information about ImmunoGenesis, including an in-depth look at their abstract, can be found on the AACR Annual Meeting website.
About ImmunoGenesis
Dedicated to revolutionizing the immuno-oncology landscape, ImmunoGenesis champions novel strategies to tackle key immune resistance mechanisms. The company’s lead product, IMGS-001, is currently undergoing a phase 1a/b clinical trial focused on immune-excluded tumors, which represent a significant challenge in cancer treatment, affecting over half of all cancer patients. ImmunoGenesis is committed to changing this dynamic, combining various mechanisms to enhance immune response within tumor environments.
For more insights into their research and developments, visit immunogenesis.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.